The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

Pfizer Inc. is offering around 700 million shares in Haleon Plc, representing a roughly 7.7% stake in the maker of Sensodyne ...

Two FTSE 100 stocks in Harvey Jones' portfolio have suffered double-digit losses. He's standing by them for now, but he's ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

She was previously the supplier's head of commercial excellence for Europe, Middle East, Africa & Latin America ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares ...

Pfizer is set to raise £2.5bn by selling a 7.7% stake in Haleon, the UK consumer healthcare company, in a block trade on ...

Pfizer is selling around 700 million ordinary shares in Haleon, reducing its stake from 15% to about 7.3%. This sale follows its earlier reduction of ownership and reflects ongoing pressure from hedge ...

The latest disposal reduced Pfizer's interest in Haleon to 7.3% from 15%. JPMorgan and Morgan Stanley acted as joint global coordinators and joint bookrunners for the sale. GSK sold its remaining 4.2% ...

GSK took a 13.5% stake in the blue chip ... (Alliance News) - Pfizer Inc sold 700 million shares in Haleon PLC, as planned, more than halving its remaining stake, placing agent JPMorgan Securiti ...